TSE:TH - Theratechnologies Stock Price, News, & Analysis

-0.44 (-5.89 %)
(As of 06/17/2019 02:33 PM ET)
Today's Range
Now: C$7.03
50-Day Range
MA: C$6.55
52-Week Range
Now: C$7.03
Volume187,516 shs
Average Volume167,218 shs
Market CapitalizationC$540.62 million
P/E RatioN/A
Dividend YieldN/A
Theratechnologies Inc, a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada and the United States; and Trogarz, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients in the United States. Read More…

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual SalesC$51.45 million
Cash FlowC$0.66 per share
Book ValueC$0.44 per share



Market CapC$540.62 million
Next Earnings Date7/4/2019 (Estimated)
OptionableNot Optionable

Receive TH News and Ratings via Email

Sign-up to receive the latest news and ratings for TH and its competitors with MarketBeat's FREE daily newsletter.

Theratechnologies (TSE:TH) Frequently Asked Questions

What is Theratechnologies' stock symbol?

Theratechnologies trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TH."

When is Theratechnologies' next earnings date?

Theratechnologies is scheduled to release their next quarterly earnings announcement on Thursday, July 4th 2019. View Earnings Estimates for Theratechnologies.

What price target have analysts set for TH?

4 analysts have issued twelve-month price targets for Theratechnologies' stock. Their forecasts range from C$10.00 to C$15.00. On average, they expect Theratechnologies' share price to reach C$12.69 in the next twelve months. This suggests a possible upside of 80.5% from the stock's current price. View Analyst Price Targets for Theratechnologies.

What is the consensus analysts' recommendation for Theratechnologies?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theratechnologies in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Theratechnologies.

Has Theratechnologies been receiving favorable news coverage?

News stories about TH stock have trended somewhat positive recently, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Theratechnologies earned a news impact score of 1.4 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Theratechnologies.

Who are some of Theratechnologies' key competitors?

What other stocks do shareholders of Theratechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Theratechnologies investors own include Stars Group (TSGI), ProMetic Life Sciences (PLI), BCE (BCE), Theratechnologies (THERF), Teranga Gold (TGZ), Nemaska Lithium (NMX), United Therapeutics (UTHR), Endeavour Mining (EDV), Shopify (SHOP) and Catalyst Pharmaceuticals (CPRX).

Who are Theratechnologies' key executives?

Theratechnologies' management team includes the folowing people:
  • Mr. Luc Tanguay, Pres, CEO & Non-Independent Director (Age 61)
  • Mr. Philippe Dubuc MBA, Sr. VP & CFO (Age 52)
  • Mr. Jocelyn Lafond, VP of Legal Affairs & Corp. Sec. (Age 51)
  • Mr. Denis Boucher B.A., L.L.B., VP of Communications & Corp. Affairs (Age 53)
  • Mr. Christian Marsolais, Sr. VP & Chief Medical Officer (Age 56)

Who are Theratechnologies' major shareholders?

Theratechnologies' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Monarch Partners Asset Management LLC (0.58%), LLBH Private Wealth Management LLC (0.24%), Mesirow Financial Investment Management Inc. (0.05%) and Virtu Financial LLC (0.01%). Company insiders that own Theratechnologies stock include Christian Marsolais, Denis Boucher, Jean-Denis Talon, Jocelyn Lafond, Luc Tanguay, Lyne Fortin, Marie-Noël Colussi and Philippe Dubuc. View Institutional Ownership Trends for Theratechnologies.

Which major investors are buying Theratechnologies stock?

TH stock was purchased by a variety of institutional investors in the last quarter, including Monarch Partners Asset Management LLC, LLBH Private Wealth Management LLC, Mesirow Financial Investment Management Inc. and Virtu Financial LLC. Company insiders that have bought Theratechnologies stock in the last two years include Christian Marsolais, Denis Boucher, Jean-Denis Talon, Luc Tanguay and Philippe Dubuc. View Insider Buying and Selling for Theratechnologies.

How do I buy shares of Theratechnologies?

Shares of TH and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Theratechnologies' stock price today?

One share of TH stock can currently be purchased for approximately C$7.03.

How big of a company is Theratechnologies?

Theratechnologies has a market capitalization of C$540.62 million and generates C$51.45 million in revenue each year. Theratechnologies employs 32 workers across the globe.View Additional Information About Theratechnologies.

What is Theratechnologies' official website?

The official website for Theratechnologies is http://www.theratech.com/.

How can I contact Theratechnologies?

Theratechnologies' mailing address is 2015 Peel St 5th Floor, MONTREAL, QC H3A 1T8, Canada. The company can be reached via phone at +1-514-3367800.

MarketBeat Community Rating for Theratechnologies (TSE TH)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  214 (Vote Outperform)
Underperform Votes:  237 (Vote Underperform)
Total Votes:  451
MarketBeat's community ratings are surveys of what our community members think about Theratechnologies and other stocks. Vote "Outperform" if you believe TH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/17/2019 by MarketBeat.com Staff

Featured Article: What is a dead cat bounce?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel